Home » Newsletters » BioWorld Science

BioWorld Science

April 24, 2013

View Archived Issues

Romark Laboratories commences enrollment in phase III trial of nitazoxanide for influenza

Impel NeuroPharma completes proof-of-concept study for nose-to-brain drug delivery technology

New prostate cancer vaccine is safe in patients

Galectin-9, a marker of radicality of cancer resection during surgery

Bayer presents novel AR antagonist with promising in vivo activity in CRPC models

Paragazole is active against triple-negative breast cancer cells

Dosing begins in phase I/II anal cancer study of ADXS-HPV

Dainippon Sumitomo Pharma presents novel mAChR partial agonists as potential antipsychotic drugs

ASLAN Pharmaceuticals to conduct antiarthritic drug study in Singapore

Companies fund Canadian Centers of Excellence for Commercialization and Research

Galapagos begins first phase II study of GLPG-0974 in ulcerative colitis

Afferent Pharmaceuticals profiles its P2X3 receptor antagonist AF-219

Merck KGaA presents novel LPA2 receptor antagonists

New CYP17 inhibitors patented at Bristol-Myers Squibb

Oncodesign discovers novel FLT3 inhibitors

Presentations describe novel mutant-selective EGFR inhibitor CNX-2006

NanoViricides anticipates efficacy of FluCide drug candidates against H7N9 influenza

Taiho Pharmaceutical designs new SYK inhibitors

Ipsen and Oncodesign prepare novel LRRK2 inhibitors

Janssen files for European approval of simeprevir for HCV

Enrollment begins in phase I trial of Acorda's remyelinating antibody candidate for MS

Takeda files for approval of fixed-dose combination drug for hypertension in Japan

FDA approves Amitiza for additional indication

CytRx reaches SPA agreement with FDA for phase III trial of aldoxorubicin

FDA grants fast track designation to KB-001A for P. aeruginosa

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
New 5-HT2C receptor agonists reported in Hansoh patent
BioWorld Science
Researchers from Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have disclosed tricyclic compounds acting as 5-HT2C receptor...
Parabilis takes top spot, pricing largest biopharma IPO at $670M
BioWorld
Less than two months after Kailera Therapeutics Inc. made headlines with biopharma’s largest IPO to date, Parabilis Medicines Inc. has come along and surpassed...